Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

• Published in: Journal for immunotherapy of cancer Vol. 8; no. 1; p. e000878
• Main Authors: Ascierto, Paolo Antonio, Fox, Bernard, Urba, Walter, Anderson, Ana Carrizosa, Atkins, Michael B, Borden, Ernest C, Brahmer, Julie, Butterfield, Lisa H, Cesano, Alessandra, Chen, Daniel, de Gruijl, Tanja, Dillman, Robert O, Drake, Charles G, Emens, Leisha A, Gajewski, Thomas F, Gulley, James L, Stephen Hodi, F, Hwu, Patrick, Kaufman, David, Kaufman, Howard, Lotze, Michael, McNeel, Douglas G, Margolin, Kim, Marincola, Francesco, Mastrangelo, Michael J, Maus, Marcela V, Parkinson, David R, Romero, Pedro J, Sondel, Paul M, Spranger, Stefani, Sznol, Mario, Weiner, George J, Wiggington, Jon M, Weber, Jeffrey S
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.04.2020; BMJ Publishing Group
• Subjects: Antibodies; Betacoronavirus; Breast cancer; Cancer; Cancer therapies; Coronavirus Infections - diagnostic imaging; Coronavirus Infections - drug therapy; Coronavirus Infections - immunology; Coronavirus Infections - therapy; Coronaviruses; COVID-19; COVID-19 vaccines; Drug Approval; FDA approval; Funding; Grants; Humans; Hypoxia; Immunologic Factors - therapeutic use; Immunotherapy; Inflammation - blood; Inflammation - therapy; Intensive care; Interleukin-6 - agonists; Medical research; Neoplasms - therapy; Pandemics; Pharmaceuticals; Pneumonia, Viral - diagnostic imaging; Pneumonia, Viral - drug therapy; Pneumonia, Viral - immunology; Pneumonia, Viral - therapy; Receptors, Interleukin-6 - agonists; Royalties; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; T cell receptors; United States > US; China; immunomodulation; inflammation mediators
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1136/jitc-2020-000878

Tocilizumab also is already FDA approved to manage cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor T cell therapy.4 5 In addition, tocilizumab has been shown to reduce toxicity in patients treated with ICIs who were steroid refractory,6 and has been added to the ICI agents ipilimumab and nivolumab in an ongoing US phase II study (NCT03999749) to ameliorate immune-related toxicity. Contracted Research: Aduro Biotech, AstraZeneca, Bristol-Myers Squibb, Corvus, EMD Serono, Genentech, F Hoffman La Roche, Maxcyte, Merck, Tempest; Consulting Fees: Genentech, F Hoffman La Roche, Syndax, Eli Lilly, AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Chugai, Genentech, F Hoffman La Roche, Gritstone, Medimmune, Macrogenics, Novartis, Peregrine, Replimune, Silverback, Vaccinex; IP Rights: Aduro Biotech; Royalty: Elsevier;Salary: University of Pittsburgh, UPMC UPP; Grants from non-industry entities: HeritX Incorporated, NSABP Foundation, Translational Breast Cancer Research Consortium, Breast Cancer Research Foundation, National Cancer Institute, Department of Defense, Johns Hopkins University, University of California San Francisco; TdG: Consulting Fees: DCPrime BV, Macrophage Pharma, Partner Therapeutics; Contracted Research: Idera Pharmaceuticals, Macrophage Parma; IP Rights/Patents: The use of cytostatics for the accelerated differentiation of DC WO2009019320-A2; WO2009019320-A3; AU2008285598-A1; EP2281030-A2; CA2724018-A1; US2011117051-A1. Advisory Board: Aduro, Amgen, 7 Hills Pharma, Compass Therapeutics, Takeda, Rheos, Surface, Verastem; Advisory Board/Equity: Poinyr; Consulting Fees: Genetech/Roche, Bayer, Bristol-Myers Squibb, EMD Serono, Kairos, Merck, Partners Therapeutics, Sanofi, Pfizer, Pieris Pharmaceutical; Scientific Advisory Board/Equity: Apricity, Torque, Bicara; Grant/Royalties to Institution: Bristol-Myers Squibb, Novartis; PH: